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In this trial, 390 insulin-treated patients with type 2 diabetes were randomized to either pla-
cebo or metformin. Fasting levels of glucose, insulin and C peptide were determined at base-
line, after 4 months and yearly thereafter for 4 years to assess fasting estimates of beta cell
function. The primary endpoint was the fasting C peptide-to-glucose ratio (FCPGR) and sec-
ondary measures were the disposition index (DI) and the fasting C peptide (FCP). We analysed
the results with a general linear mixed model. Baseline FCPGR was 5.27 (95% CI, 4.83 – 5.71).
Compared to placebo, FCPGR increased in the metformin group with 1.48 (95% CI, 1.09 –
1.87, P < 0.001). The DI showed comparable results with a treatment effect of 1.50 (95% CI,
1.17 – 1.83; P < 0.001). FCP also increased in the metformin group but did not reach statistical
significance vs placebo (0.034 nmol, 95% CI, −0.005 – 0.072; P = 0.085). Treatment with met-
formin vs placebo, added to insulin in patients with type 2 diabetes, improves long-term esti-
mates of beta cell function in the fasting state.
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1 | INTRODUCTION
Metformin is a key drug in the treatment of type 2 diabetes. In the
Hyperinsulinaemia: the Outcome of its Metabolic Effects (HOME)
study,1 we showed that metformin improved glycaemic control and
decreased insulin requirements compared with placebo in insulin-
treated patients with advanced type 2 diabetes. In this respect, met-
formin is generally regarded as an insulin sensitizer. Whether metfor-
min can also improve β-cell function is not clear. In the present
analysis of the HOME study, we studied the effects of metformin vs
placebo on estimates of fasting β-cell function. In addition, we quanti-
fied the durability of metformin’s effect on these estimates over a
period of 4.3 years.
2 | METHODS
2.1 | Study design and patients
In the HOME study, 390 insulin-treated patients with advanced type
2 diabetes were randomly allocated to either metformin 850 mg
(up to 3 times daily if tolerated) or matching identical-looking placebo
through a computer program. Most patients (n = 345) were already
using monotherapy insulin, either twice-daily premixed NPH/regular
insulin (Novomix) or NPH insulin in the evening combined with pran-
dial regular insulin. The remaining 45 patients used a combination of
metformin and insulin, and discontinued metformin 3 months before
randomization.
Received: 17 June 2017 Revised: 12 September 2017 Accepted: 21 September 2017
DOI: 10.1111/dom.13123
730 © 2017 John Wiley & Sons Ltd wileyonlinelibrary.com/journal/dom Diabetes Obes Metab. 2018;20:730–733.
All participants provided written informed consent and the study
was approved by the medical ethics committees of the 3 participating
non-academic hospitals. Study visits took place at baseline and at
1 month, and 3-monthly thereafter, with a follow up of 4.3 years.
2.2 | Measures
Blood samples for this analysis of the HOME trial were drawn at
baseline and after 4, 17, 30, 43 and 52 months, and were stored at
−80C until analysis. C-peptide plasma samples were available for
363 patients at baseline and at ≥1 follow-up visit(s) (93%), and for
259 patients at their final visit (66%), and were taken using a solid-
phase, chemiluminescent enzyme immunoassay (Immulite 2000;
Siemens, Camberley, UK). Serum insulin was measured by electroche-
miluminescence immunoassay (Modular E170; Roche Diagnostics,
Basel, Switzerland). Coefficients of variation are provided in Appendix
S1. Because patients used human basal insulin (Insulatard; Novo Nor-
disk, Bagsværd, Denmark) there was full cross-reactivity between
endogenous insulin and exogenous insulin in this assay.
The primary estimate of β-cell function was fasting C-peptide
(FCP)-to-fasting plasma glucose (FPG) ratio. To normalize our ratio
based on SI units, we used an arbitrary constant of 100 for conve-
nience, resulting in the unitless formula FCP:FPG ratio = 100 × FCP/
FPG. As secondary measures we used FCP and the disposition index
(DI), defined as the FCP:FPG ratio adjusted for insulin sensitivity (IS),
resulting in the unitless formula DI = FCP:FPG ratio × IS0.2. IS was
calculated from FPG and FPI using the unitless formula IS = 1000/
FPG × FPI. (For further details see Appendix S1.)
2.3 | Statistical analysis
We used all measurements to assess the effects of metformin vs pla-
cebo during the entire follow-up period. To quantify the overall treat-
ment effect over time, we used a linear mixed model, simultaneously
assessing the significance of the main time effect, main metformin
treatment effect, and interaction of metformin treatment effect with
time (Appendix S1).
In addition, we conducted a mediation analysis to assess the indi-
rect (mediating) effect of glycated haemoglobin (HbA1c) in the change
of FCP:FPG ratio. For this purpose, we added HbA1c as a covariate in
the model, and evaluated the mediating HbA1c effect by the product
of the effects (metformin ! HbA1c) and (HbA1c ! FCP:FPG ratio)
and confidence interval (CI), calculated by bootstrapping (details in
Appendix S1).
3 | RESULTS
Figure 1A–C show the time course of HbA1c, β-cell function and IS
during all visits. Table 1 shows the results of the mixed linear model
in which, for each variable, the baseline value, time effect, treatment
effect and time–treatment interaction are shown. Treatment effect in
the model is defined as the constant post-baseline change in the met-
formin group vs placebo, expressed as an absolute change. In
addition, this change is described as a relative change compared with
baseline.
Compared with the placebo group, the FCP:FPG ratio increased in
the metformin group. Mixed-model results showed a constant treat-
ment effect from the first post-baseline visit until the end of the trial
of 1.48 (95% CI, 1.09 to 1.87; P < .001), no change in time (0.00/year,
95% CI, –0.001 to +0.001; P = .92) and no time–treatment interaction
(−0.010/year, 95% CI, –0.021 to 0.001; P = .058). Relative to baseline,
the treatment effect was 28% (95% CI, 23 to 33).
The DI results were similar to those observed with the FCP:FPG
ratio: a small decrease in the placebo group and an increase in the
metformin group. Mixed-model results confirmed a significant
decrease in time of −0.01/year (95% CI, –0.01 to −0.001; P = .023)
for the placebo group, a constant treatment effect during the whole
post baseline period of 1.50 (95% CI, 1.17 to 1.83; P < .001), and no
time-treatment interaction (−0.01 [95% CI, –0.02 to 0.00]; P = .128).
Relative to baseline, the treatment effect was 32% (95% CI, 27 to 36).
The FCP level decreased in the placebo group and increased in the
metformin group. Mixed-model results showed a non-significant treat-
ment effect (0.034 nmol [95% CI, –0.005 to 0.072; P = .085), no time
effect (0.00 nmol/L/year [95% CI, –0.00 to 0.00]; P = .61), and no time–
treatment interaction (0.00 nmol/L/year, 95% CI, –0.00 to 0.00; P = .26).
Relative to baseline, the treatment effect was 7% (95% CI, –1 to 14).
The HbA1c level increased in the placebo group and decreased
in the metformin group. Mixed-model results confirmed a significant
change in time of 0.07%/year in the placebo group (95% CI, 0.04 to
0.10; P < .001), a treatment effect of −0.93% (95% CI, –1.06 to
−0.80; P < .001) from the first post-baseline visit until the end of the
trial, and a time–treatment interaction of 0.011%/year (95% CI,
0.008 to 0.015; P < .001).
We assessed the indirect (mediating) effect of HbA1c in FCP:FPG
ratio improvement by adding HbA1c as a covariate in the model. In
comparison with the initial model, the mediating effect of HbA1c (met-
formin ! HbA1c ! FCP:FPG ratio) on the overall effect (metformin
! FCP:FPG ratio) was small (0.53 [95% CI, 0.45 to 0.73]), accounting
for a small proportion of the variance (36.1% [95% CI, 25.4 to 49.5]).
There was an increase in IS in the metformin group and a
decrease in the placebo group. Mixed-model results showed a treat-
ment effect of 0.33 (95% CI, 0.03 to 0.63; P = .031), no significant
change in time for the placebo group (0.00/year, 95% CI, –0.00 to
0.01; P = .69), and no time–treatment interaction (−0.00/year [95%
CI, –0.01 to 0.01]; P = .612). Relative to baseline, the treatment
effect was 36% (95% CI, 3 to 69).
4 | DISCUSSION
The present study shows that metformin added to insulin improves
fasting based estimates of β-cell function durably in comparison with
placebo. These effects were for the most part (64%) independent of
changes in glycaemic control. Additionally adjusting for IS, by calcu-
lating the DI, did not alter the results.
Depending on the estimate used, the increase in β-cell function
was 28% (95% CI, 23 to 33) for FCP:FPG ratio and 32% (95% CI,
27 to 36) for DI. IS, assessed by a homeostatic model assessment
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(HOMA)-derived fasting index, also improved by 36% (95% CI,
3 to 69).
A C-peptide with a concurrent glucose level of >8 mmol/L might
be considered a non-fasting value.2 This did apply to our population
with a mean FPG at baseline of 10 mmol/L. To adjust for this hypergly-
caemic stimulus, we chose the FCP:FPG ratio as our primary endpoint.
Meier et al.3 reported a good correlation of FCP:FPG ratio with
human pancreatic β-cell mass in a small group of patients who under-
went pancreatic surgery. Okuno et al.4 showed in a much bigger pop-
ulation of patients with type 2 diabetes, that FCP:FPG ratio strongly
correlates with accepted measures as the HOMA-β (r = 0.79) and
hyperglycaemic clamp (increase in Area Under the Curve insulin/glu-
cose 90 minutes, r = 0.721).
Because β-cell function depends on prevailing IS, we adjusted for IS
by calculating the DI. The use of exogenous insulin may confound the
assessment of IS, unless a steady-state has been achieved without rapid
changes in glucose transport.5 In the present study, fasting insulin levels
were drawn in the morning, during which a standard condition
(a certain steady-state) of intermediate-acting NPH insulin levels had
been achieved without fast changes in insulin-driven glucose transport.
Further, a valid DI should incorporate independent estimates of β-cell
function and IS.6 Because we used C-peptide-based data for our β-cell
estimate and insulin-based data for our IS estimate, we avoided intrinsi-
cally interdependent estimates. To assess this independency, we per-
formed an additional correlation analysis that showed a weak
correlation (r = 0.29 [95% CI 0.19 to 0.38) for C-peptide and insulin.
TABLE 1 Mixed-model fixed effect estimates
FCP:FPG ratio DI C-peptide, nmol/L IS HbA1c, %
Baseline 5.27 (4.83; 5.71) 4.73 (4.36; 5.10) 0.50 (0.46; 0.54) 0.90 (0.74; 1.07) 7.79 (7.68; 7.89)
Treatment effecta 1.48* (1.09; 1.87) 1.50* (1.17; 1.83) 0.03 (0.00; 0.07) 0.33* (0.03; 0.63) −0.93* (−1.06; −0.80)
Time effect −0.00 (−0.09; 0.08) −0.08* (−0.15; −0.01) 0.00 (−0.01; 0.01) 0.01 (−0.05; 0.08) 0.07* (0.04; 0.10)
Time–treatment interaction −0.12 (−0.26; 0.01) −0.09 (−0.20; 0.02) 0.01 (−0.01; 0.02) −0.03 (−0.14; 0.08) 0.14* (0.09; 0.18)
Data are estimates (95% CI). Time effect and time–treatment interaction are expressed as change per year.
*P < .05. aConstant treatment effect from the first post-baseline visit until the end of the study.
FIGURE 1 Time course of A, HbA1c; B, FCP:FPG ratio and C, IS. Data are given as means with standard error of the mean
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Although the improvements in β-cell function and IS were main-
tained during the 4.3-year follow-up period, there was no time–
treatment interaction for either β-cell function or IS, indicating that
the improvement constitutes an immediate treatment effect without
additional change over time relative to placebo.
Two major trials7,8 have evaluated long-term metabolic changes
related to β-cell function in metformin users as compared with other
treatments: the UK Prospective Diabetes Study (UKPDS) and A Dia-
betes Outcome Progression Trial (ADOPT). Both trials also observed
modest improvement in β-cell function in metformin users; however,
in the UKPDS, long-term follow-up of β-cell function is difficult to
interpret because of the slowly rising FPG levels during the study and
their influence on the HOMA-β estimate that was used.9
In ADOPT, apart from HOMA-β, the oral glucose tolerance test was
used as an estimate of β-cell function. It was shown that metformin dur-
ing 4 years of follow-up improved β-cell function as compared with gly-
buride, although this was less pronounced than with rosiglitazone and
had a much smaller effect size (2.5%) than in the present study (28%).
This discrepancy may be partially explained by differences between
the study populations. Patients included in ADOPT were newly diag-
nosed patients, while in the HOME study, patients with advanced diabe-
tes receiving insulin therapy were included. Advanced type 2 diabetes is
characterized by more β-cell failure than new-onset type 2 diabetes, and
may have more potential for improvement (provided β-cell damage is
partially reversible). Moreover, our placebo-controlled design allows a
comparison with placebo instead of the comparator-based design of
ADOPT.
Although metformin has no direct short-term insulin secretory
effects on the β cells of normal glucose-tolerant individuals,10,11 mul-
tiple mechanisms may explain its β-cell-enhancing effect in patients
with type 2 diabetes. Apart from decreased glucotoxicity, improved
incretin secretion12,13 and reduced lipotoxicity14 may be involved in
the action of metformin to improve β-cell function.
The present study is limited by studying the effects of metformin
on estimates of β-cell function and IS in the fasting state. Effects of
metformin through the incretin system, which were not assessed in
the present study, may also improve prandial β-cell function.
In conclusion, the present study shows that metformin results in
long-term improvement in fasting estimates of β-cell function in addition
to an improvement in IS, contributing to a durably improved glycaemic
control in insulin-treated patients, even in advanced type 2 diabetes.
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